Valneva SE (VALN) Research & Development (2021 - 2026)
Valneva SE's (VALN) quarterly Research & Development came in at -$17.8 million in Q1 2026, down 13.25% year-on-year from -$20.5 million in Q1 2025, and down 110.55% quarter-over-quarter from $168.8 million in Q4 2025.
Valneva SE (VALN) Research & Development (2021 - 2026) Analysis & Trends
Valneva SE has disclosed Research & Development across 6 years of filings, most recently posting -$17.8 million for Q1 2026.
- Research & Development for Q1 2026 came in at -$17.8 million, down 13.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $99.3 million (up 29.26% YoY), and the FY2025 annual result was $99.3 million, up 25.33% from the prior year.
- Research & Development came in at -$17.8 million for Q1 2026 at Valneva SE, down from $168.8 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $184.0 million in Q4 2022 to a low of -$33.3 million in Q2 2022.
- The 5-year median for Research & Development is -$17.7 million (2023), against an average of $19.4 million.
- Across the five-year window, Research & Development surged 61.03% in 2023 and tumbled 53.82% in 2025, its largest moves.
- Valneva SE's Research & Development stood at $184.0 million in 2022, then sank by 40.28% to $109.9 million in 2023, then gained by 19.35% to $131.1 million in 2024, then gained by 28.75% to $168.8 million in 2025, then slumped by 110.55% to -$17.8 million in 2026.
- The last three Research & Development figures came in at -$17.8 million (Q1 2026), $168.8 million (Q4 2025), and -$31.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -58.00 Mn |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | -17.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.81 Mn |
| Dec 31, 2025 | 168.82 Mn |
| Sep 30, 2025 | -31.90 Mn |
| Jun 30, 2025 | -19.80 Mn |
| Mar 31, 2025 | -15.73 Mn |
| Dec 31, 2024 | 131.13 Mn |
| Sep 30, 2024 | -20.74 Mn |
| Jun 30, 2024 | -17.82 Mn |
| Mar 31, 2024 | -14.27 Mn |
| Dec 31, 2023 | 109.87 Mn |
| Sep 30, 2023 | -17.68 Mn |
| Jun 30, 2023 | -12.97 Mn |
| Mar 31, 2023 | -15.10 Mn |
| Dec 31, 2022 | 183.96 Mn |
| Sep 30, 2022 | -23.70 Mn |
| Jun 30, 2022 | -33.29 Mn |
| Mar 31, 2022 | -23.22 Mn |
| Dec 31, 2021 | 332.34 Mn |
| Sep 30, 2021 | -45.40 Mn |
| Jun 30, 2021 | -61.42 Mn |